SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF
 THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported):  September 29, 2017 (September 28, 2017)


CHEMBIO DIAGNOSTICS, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
  
0-30379
  
88-0425691
(State or other jurisdiction
  
(Commission File Number)
  
(IRS Employer
of Incorporation)
      
Identification Number)
   
3661 Horseblock Road
    
   
Medford, NY 11763
    
   
(Address of principal executive offices)
    
   
631-924-1135
    
   
(Registrant's Telephone Number)
    
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 


ITEM 8.01.   OTHER EVENTS.

On September 28, 2017, the Company issued a press release entitled "Chembio Diagnostics Receives FDA Emergency Use Authorization for the First Rapid Zika IgM Test".  A copy of the press release is included herewith as Exhibit 99.1 and incorporated herein by reference.


ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibits.

99.1
Press Release entitled "Chembio Diagnostics Receives FDA Emergency Use Authorization for the First Rapid Zika IgM Test" dated September 28, 2017.
   
 
 
 
 
 


  


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


September 29, 2017                                                                   Chembio Diagnostics, Inc.




By:    /s/ Sharon Klugewicz                                      
Sharon Klugewicz
Acting Chief Executive Officer
 

 
 
EXHIBIT INDEX
Exhibit Number
Description
99.1
Press Release entitled "Chembio Diagnostics Receives FDA Emergency Use Authorization for the First Rapid Zika IgM Test" dated September 28, 2017.